<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Experimental Psychology</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/0D476B57-83D7-40C9-AC5D-EC980E83BB10"><gtr:id>0D476B57-83D7-40C9-AC5D-EC980E83BB10</gtr:id><gtr:firstName>Zoltan</gtr:firstName><gtr:surname>Molnar</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/19D1396C-ECFC-4111-9838-02133E0C97EF"><gtr:id>19D1396C-ECFC-4111-9838-02133E0C97EF</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:surname>Harrison</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/95DF1C05-09A0-412A-87F2-6D0A6175BFD7"><gtr:id>95DF1C05-09A0-412A-87F2-6D0A6175BFD7</gtr:id><gtr:firstName>Matthew</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Wood</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/5A8DE84E-CB9F-43AE-A532-95AB90F7432C"><gtr:id>5A8DE84E-CB9F-43AE-A532-95AB90F7432C</gtr:id><gtr:firstName>Philip</gtr:firstName><gtr:otherNames>William</gtr:otherNames><gtr:surname>Burnet</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/D291BB52-224A-4E06-A1A5-37FD07033E6A"><gtr:id>D291BB52-224A-4E06-A1A5-37FD07033E6A</gtr:id><gtr:firstName>Sharon</gtr:firstName><gtr:otherNames>Lisa</gtr:otherNames><gtr:surname>Eastwood</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0500180"><gtr:id>2AFDA1C1-B838-4541-975A-6E3BE36567B8</gtr:id><gtr:title>The expression and function of glutamatergic susceptibility genes in schizophrenia</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0500180</gtr:grantReference><gtr:abstractText>A number of genes that may affect people?s risk of getting schizophrenia have recently been identified. Although the evidence is still incomplete, it has been suggested that they share in common an effect on how a key chemical transmitter, called glutamate, functions in the brain. We want to investigate this question further, to help understand the mechanisms by which the genes work. To do this, we will study in detail where exactly the genes are expressed in the brain, what the differences are in people with the illness, and between people with different variants (?polymorphisms?) of each gene. We will also study, in various experimental models, the consequences of manipulating the genes in a way that mimics the alterations seen in the illness. Overall, our objective is to discover important clues about the genetic and biological abnormalities that underlie schizophrenia, and which may help in the development of better drug treatments.</gtr:abstractText><gtr:technicalSummary>A number of susceptibility genes for schizophrenia have recently been identified. There are two notable features of the findings. First, most of the genes are thought to have their primary actions upon glutamatergic synaptic transmission, consistent with prior evidence of glutamatergic and synaptic dysfunction in schizophrenia affecting NMDAR transmission. Second, the genetic variants that are associated with the disease are virtually all non-coding; as such, they probably exert their effects via altered gene expression. This combination of discoveries leads to the hypothesis that abnormalities of the glutamatergic synapse are a core pathophysiological mechanism for schizophrenia, arising from alterations in some facet of expression of the genes. This project, which is in essence a targeted functional genomics study, has three components. (1) We will study five of the genes (DAOA, DAAO, GRM3, CNAalpha, ZDHHC8), in detail in adult human and developing brain, to identify the location and ontogeny of their mRNA and protein expression, using a range of methods. (2) We will establish whether the expression of the genes is affected by schizophrenia or by genetic polymorphisms, using large series of human brain tissue. We predict that these components will reveal expression profiles supportive of a genetically-mediated impairment of NMDAR signalling in schizophrenia. (3) The final component comprises experimental studies to address complementary issues which are impractical in human brain (e.g. ultrastructural immunolocalisation, embryological studies), and in order to examine the causes and consequences, in vitro, of up- and down-regulation of expression of the genes. In total, the project is translational, revealing not only the differences in expression of these genes in schizophrenia, but also using experimental systems to inform the human work and to identify the molecular basis and functional correlates of the altered expression. Identification of a convergent, genetically influenced, biochemical pathway would be a major advance for the understanding of schizophrenia, and a basis for targeted pharmacotherapeutic interventions to modify the disease process rather than merely suppress its symptoms. This project will contribute significantly to this ambitious but now realistic goal.</gtr:technicalSummary><gtr:fund><gtr:end>2009-09-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>662531</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Translational studies of group II metabotropic glutamate receptors (mGluR2, mGluR3) and their role in schizophrenia</gtr:description><gtr:id>90EFD352-C7BE-40AB-9EBA-16AF1F1A931A</gtr:id><gtr:impact>Helped lead to an MRC pilot industry award between ourselves and GSK, funded in October 2008.</gtr:impact><gtr:partnerContribution>Facilitated other interactions with, and support from, GSK</gtr:partnerContribution><gtr:piContribution>Generated idea, and leading on experimental work.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>School visit - by Sharon Eastwood</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>7F8375B9-87FD-4E30-9716-35182530D1D4</gtr:id><gtr:impact>Talked in school about nature of science and specifics of own research.

Not known</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visit</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>BD6E2E5A-158A-4F03-9A64-53159F4FE1E6</gtr:id><gtr:impact>Gave lectures and answered questions about schizophrenia, its genes, and its overall causation.

Interest from students in psychology and neuroscience as a career.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2008,2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>391000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Strategic Grant</gtr:description><gtr:end>2011-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>49F6B855-AFFF-40A0-BB4D-F8AE9782388D</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/970F6AB3-696F-4083-B942-6000CF0A2AC9"><gtr:id>970F6AB3-696F-4083-B942-6000CF0A2AC9</gtr:id><gtr:title>Six degrees of separation: on the prior probability that schizophrenia susceptibility genes converge on synapses, glutamate and NMDA receptors.</gtr:title><gtr:parentPublicationTitle>Molecular psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/05e91aca2dd795fe44436811684414dd"><gtr:id>05e91aca2dd795fe44436811684414dd</gtr:id><gtr:otherNames>Harrison PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1359-4184</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B7162F27-0CDD-4B4F-BFE3-B212745B5A5A"><gtr:id>B7162F27-0CDD-4B4F-BFE3-B212745B5A5A</gtr:id><gtr:title>The neurobiology of D-amino acid oxidase and its involvement in schizophrenia.</gtr:title><gtr:parentPublicationTitle>Molecular psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a1b41594fdc9f2f7f7b3671ae3e9bdc9"><gtr:id>a1b41594fdc9f2f7f7b3671ae3e9bdc9</gtr:id><gtr:otherNames>Verrall L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1359-4184</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/57F2E5B0-E9DD-485A-AE32-4E0FC8A082D1"><gtr:id>57F2E5B0-E9DD-485A-AE32-4E0FC8A082D1</gtr:id><gtr:title>d-Amino acid oxidase and serine racemase in human brain: normal distribution and altered expression in schizophrenia.</gtr:title><gtr:parentPublicationTitle>The European journal of neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a1b41594fdc9f2f7f7b3671ae3e9bdc9"><gtr:id>a1b41594fdc9f2f7f7b3671ae3e9bdc9</gtr:id><gtr:otherNames>Verrall L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0953-816X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DA80529C-C70B-40B6-9C28-E02A1AE133E3"><gtr:id>DA80529C-C70B-40B6-9C28-E02A1AE133E3</gtr:id><gtr:title>Expression of kinase interacting with stathmin (KIS, UHMK1) in human brain and lymphoblasts: Effects of schizophrenia and genotype.</gtr:title><gtr:parentPublicationTitle>Brain research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f23939100b02e31d3f9a4cdf6009d68d"><gtr:id>f23939100b02e31d3f9a4cdf6009d68d</gtr:id><gtr:otherNames>Bristow GC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-8993</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/75F375F5-F1FD-4FA4-BA00-DCE0A56A6932"><gtr:id>75F375F5-F1FD-4FA4-BA00-DCE0A56A6932</gtr:id><gtr:title>Markers of glutamate synaptic transmission and plasticity are increased in the anterior cingulate cortex in bipolar disorder.</gtr:title><gtr:parentPublicationTitle>Biological psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/dce9ac85245d07687e2afdd745c05c8b"><gtr:id>dce9ac85245d07687e2afdd745c05c8b</gtr:id><gtr:otherNames>Eastwood SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-3223</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/36D0AF57-5289-4A04-BC7C-DFC8AA721AD2"><gtr:id>36D0AF57-5289-4A04-BC7C-DFC8AA721AD2</gtr:id><gtr:title>D-amino acid oxidase activity and expression are increased in schizophrenia.</gtr:title><gtr:parentPublicationTitle>Molecular psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/88f1f51fcbd873377fbc0243807e5763"><gtr:id>88f1f51fcbd873377fbc0243807e5763</gtr:id><gtr:otherNames>Burnet PW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1359-4184</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D89422A0-A709-4526-BB2B-DBA89F4D036C"><gtr:id>D89422A0-A709-4526-BB2B-DBA89F4D036C</gtr:id><gtr:title>Schizophrenia susceptibility genes and neurodevelopment.</gtr:title><gtr:parentPublicationTitle>Biological psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/05e91aca2dd795fe44436811684414dd"><gtr:id>05e91aca2dd795fe44436811684414dd</gtr:id><gtr:otherNames>Harrison PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0006-3223</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BE87D0D8-1FF1-4903-8860-DAF904BCDF1A"><gtr:id>BE87D0D8-1FF1-4903-8860-DAF904BCDF1A</gtr:id><gtr:title>The DISC1 Ser704Cys substitution affects centrosomal localization of its binding partner PCM1 in glia in human brain.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/dce9ac85245d07687e2afdd745c05c8b"><gtr:id>dce9ac85245d07687e2afdd745c05c8b</gtr:id><gtr:otherNames>Eastwood SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CF1C1F83-AC14-4B52-8A36-A2C7193A9D62"><gtr:id>CF1C1F83-AC14-4B52-8A36-A2C7193A9D62</gtr:id><gtr:title>Decreased mRNA expression of netrin-G1 and netrin-G2 in the temporal lobe in schizophrenia and bipolar disorder.</gtr:title><gtr:parentPublicationTitle>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/dce9ac85245d07687e2afdd745c05c8b"><gtr:id>dce9ac85245d07687e2afdd745c05c8b</gtr:id><gtr:otherNames>Eastwood SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0893-133X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/87610D5C-41F1-47E4-84CA-D5DA8579CF6C"><gtr:id>87610D5C-41F1-47E4-84CA-D5DA8579CF6C</gtr:id><gtr:title>What causes aberrant salience in schizophrenia? A role for impaired short-term habituation and the GRIA1 (GluA1) AMPA receptor subunit.</gtr:title><gtr:parentPublicationTitle>Molecular psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2a9de1982208ef86b3dcf7017290e205"><gtr:id>2a9de1982208ef86b3dcf7017290e205</gtr:id><gtr:otherNames>Barkus C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1359-4184</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/66142A93-18DE-4338-AC4A-D926F3DDB3E5"><gtr:id>66142A93-18DE-4338-AC4A-D926F3DDB3E5</gtr:id><gtr:title>DISC-1 Leu607Phe alleles differentially affect centrosomal PCM1 localization and neurotransmitter release.</gtr:title><gtr:parentPublicationTitle>Molecular psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/dce9ac85245d07687e2afdd745c05c8b"><gtr:id>dce9ac85245d07687e2afdd745c05c8b</gtr:id><gtr:otherNames>Eastwood SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1359-4184</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/441F5383-AA3C-45DB-9EE9-1A6F7840BCA3"><gtr:id>441F5383-AA3C-45DB-9EE9-1A6F7840BCA3</gtr:id><gtr:title>Expression of D-serine and glycine transporters in the prefrontal cortex and cerebellum in schizophrenia.</gtr:title><gtr:parentPublicationTitle>Schizophrenia research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/88f1f51fcbd873377fbc0243807e5763"><gtr:id>88f1f51fcbd873377fbc0243807e5763</gtr:id><gtr:otherNames>Burnet PW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0920-9964</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DF505D17-0F08-4D22-9D26-887F4167F5E0"><gtr:id>DF505D17-0F08-4D22-9D26-887F4167F5E0</gtr:id><gtr:title>Schizophrenia susceptibility genes and their neurodevelopmental implications: focus on neuregulin 1.</gtr:title><gtr:parentPublicationTitle>Novartis Foundation symposium</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/05e91aca2dd795fe44436811684414dd"><gtr:id>05e91aca2dd795fe44436811684414dd</gtr:id><gtr:otherNames>Harrison PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1528-2511</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0500180</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>3C193D18-12BD-4B15-8347-037BA623E0FF</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Mental Health</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>